Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study
By Colin Kellaher
Merck & Co. has ended part of a late-stage study of a co-formulation of its blockbuster cancer drug Keytruda in certain skin-cancer patients because the study was likely to fail.
Merck, which is studying the co-formulation of Keytruda with its investigational anti-TIGIT antibody vibostolimab compared to Keytruda alone as adjuvant treatment for patients with resected high-risk melanoma, on Monday said it ended the co-formulation arm after data showed that the primary endpoint of recurrence-free survival had met pre-specified futility criteria.
The Rahway, N.J., drugmaker said a higher rate of discontinuation of all adjuvant therapy by patients in the co-formulation arm, primarily due to immune-mediated adverse experiences, made it highly unlikely that the trial could achieve a statistically significant improvement in recurrence-free survival.
Merck said it is recommending that patients receiving the co-formulation be offered the option to be treated with Keytruda monotherapy.
Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, in a raft of trials across a wide variety of cancers and treatment settings, including a development program evaluating the vibostolimab co-formulation alone and in combination with other agents.
Keytruda, which is approved in dozens of indications worldwide, generated sales of more than $25 billion last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 13, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase